Ginkgo Bioworks Holdings (DNA) Interest Coverage Ratio (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Interest Coverage Ratio came in at 24.27 in Q1 2026, up 18.57% YoY from 20.47 in Q1 2025, and down 28714.87% on a QoQ basis from 0.08 in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Interest Coverage Ratio data on file, last reported at 24.27 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 18.57% year-over-year to 24.27 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 101.22 (up 40.57% YoY) and the FY2025 annual result came in at 0.38, up 48.25% from the prior year.
- Interest Coverage Ratio retreated to 24.27 in Q1 2026, from 0.08 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 21.62 in Q2 2024 to a low of 30.21 in Q3 2025.
- A 5-year average of 6.52 and a median of 4.84 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio plunged 16165.5% — and 2024, when it jumped 546.69%.
- Tracing DNA's Interest Coverage Ratio over 5 years: stood at 0.28 in 2022, then sank by 630.68% to 2.02 in 2023, then surged by 32.93% to 1.36 in 2024, then soared by 93.8% to 0.08 in 2025, then slumped by 28714.87% to 24.27 in 2026.
- The last three Interest Coverage Ratio figures came in at 24.27 (Q1 2026), 0.08 (Q4 2025), and 30.21 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -20.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.09 |
| Mar 31, 2026 | -24.27 |
| Dec 31, 2025 | -0.08 |
| Sep 30, 2025 | -30.21 |
| Jun 30, 2025 | -22.02 |
| Mar 31, 2025 | -29.80 |
| Dec 31, 2024 | -1.36 |
| Sep 30, 2024 | 5.97 |
| Jun 30, 2024 | 21.62 |
| Mar 31, 2024 | -0.23 |
| Dec 31, 2023 | -2.02 |
| Sep 30, 2023 | 19.07 |
| Jun 30, 2023 | -4.84 |
| Mar 31, 2023 | -5.70 |
| Dec 31, 2022 | -0.28 |
| Sep 30, 2022 | -12.87 |
| Jun 30, 2022 | -14.81 |
| Mar 31, 2022 | -9.07 |
| Dec 31, 2021 | -3,057.60 |
| Sep 30, 2021 | -0.08 |